Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Literature Highlights

Literature review thumbnail: Literature Highlights - July 2024
View Slides

Literature Highlights - July 2024

Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.

more…

Keywords:

Upadacitinib, Elsubrutinib, Efficacy, Safety, LLDAS

Publications

Clear Search

Showing 1 result for “Heguilen R.”.

October 2023
Publication thumbnail: Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center View Slides

Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center

, , ,

doi: 10.1177/09612033231204070 Epub ahead of print

Single-centre study concludes that adding belimumab to the standard of care treatment with mycophenolate (MMF) increases the possibility of achieving a complete clinical response (CCR), complete histological response (CHR), and a lower rate of relapses during treatment and long follow-up.

more…

Keywords: